1. Home
  2. BTMD vs LUNG Comparison

BTMD vs LUNG Comparison

Compare BTMD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biote Corp.

BTMD

Biote Corp.

HOLD

Current Price

$2.22

Market Cap

64.4M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.28

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTMD
LUNG
Founded
2012
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.4M
57.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BTMD
LUNG
Price
$2.22
$1.28
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$2.83
$5.38
AVG Volume (30 Days)
303.3K
326.3K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
722.22
7.64
EPS
0.74
N/A
Revenue
$192,219,000.00
$90,497,000.00
Revenue This Year
$2.03
$2.48
Revenue Next Year
$6.58
$18.46
P/E Ratio
$3.03
N/A
Revenue Growth
N/A
8.01
52 Week Low
$1.27
$1.13
52 Week High
$4.75
$5.46

Technical Indicators

Market Signals
Indicator
BTMD
LUNG
Relative Strength Index (RSI) 69.22 40.47
Support Level $2.02 $1.27
Resistance Level $2.79 $1.64
Average True Range (ATR) 0.15 0.10
MACD 0.08 0.00
Stochastic Oscillator 85.39 10.96

Price Performance

Historical Comparison
BTMD
LUNG

About BTMD Biote Corp.

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: